Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol®

Redox Report

Volumn 13, Issue 6, 2008, Pages 271-276

  Belcaro, G ^a   Cesarone, M R ^a   Errichi, S ^a   Zulli, C ^a   Errichi, B M ^a   Vinciguerra, G ^a   Ledda, A ^a   Di Renzo, A ^a   Stuard, S ^a   Dugall, M ^a   Pellegrini, L ^a   Gizzi, G ^a   Ippolito, E ^a   Ricci, A ^a   Cacchio, M ^a   Cipollone, G ^a   Ruffini, I ^a   Fano, F ^a   Hosoi, M ^a   Rohdewald, P ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

CRP; Inflammation; Osteoarthritis; Pycnogenol

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; FREE RADICAL; PLACEBO; PYCNOGENOL;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVENING DOSAGE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFECTION; JOINT FUNCTION; KNEE OSTEOARTHRITIS; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; TREATMENT DURATION; WALKING;

ADJUVANTS, IMMUNOLOGIC; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; FLAVONOIDS; FREE RADICALS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 58049192949     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100008X309019     Document Type: Article

References (32)

1. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007; 213: 626-634.
2. Krasnokutsky S, Samuels J, Abramson SB. Osteoarthritis in 2007. Bull NYU Hosp Joint Dis 2007; 65: 222-228.
3. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000; 59: 71-74.
4. Pearle AD, Scanzello CR, George S et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15: 516-523.
5. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
6. Resch KL, Hill S, Ernst E. Use of complimentary therapies by individuals with 'arthritis'. Clin Rheumatol 1997; 16: 391-395.
7. Farid R, Mirteizi A, Mirheidari M et al. Pycnogenol® supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutr Res 2007; 27: 692-697.
8. Cisár P, Jány R, Waczuliková I et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytother Res 2008; 22: 1087-1092.
9. United States Pharmacopeial Convention. United States Pharmacopoeia: Maritime Pine Extract. USP edition 28. Rockville, MD: United States Pharmacopeial Convention, 2005; 2115-2116.
10. Kohama T, Suzuki N, Ohno S, Inoue M. Analgesic efficacy of Pycnogenol® in dysmenorrhea. An open clinical trial. J Reprod Med 2004; 49: 828-832.
11. Suzuki N, Uebaba K, Kohama T et al. French maritime pine bark extract significantly lowers the requirements for analgesic medication in dysmenorrhea: A multicenter, randomized, double-blind, placebo-controlled study. J Reprod Med 2008; 53: 338-346.
12. Kohama T, Herai K, Inoue M. Effect of French maritime pine bark extract on endometriosis as compared to leuprorelin acetate. J Reprod Med 2007; 52: 703-708.
13. Belcaro G, CesaroneMR, Errichi S et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res 2008; 22: 518-523.
14. Cesarone MR, Belcaro G, Nicolaides AN et al. 'Real' epidemiology of varicose veins and chronic venous diseases: The San Valentino Vascular Screening Project. Angiology 2002; 53: 119-130
15. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039-1049.
16. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT. A simple test to monitor oxidative stress. Int Angiol 1999; 18: 127-130.
17. Komatsu F, Kagawa Y, Sakuma M et al. Investigation of oxidative stress and dietary habits in Mongolian people, compared to Japanese people. Nutr Metab (Lond) 2006; 3: 21.
18. Rohdewald P, Pycnogenol®, French maritime pine bark extract. In: Coates PM, Blackman MR, Cragg G, Levine M, Moss J, White J. (eds) Encyclopedia of dietary supplements. New York: Marcel Dekker, 2005; 545-253.
19. Grimm T, Chovanová Z, Muchová J et al. Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol®). J Inflamm 2006; 3: 1-15.
20. Schäfer A, Chovanova Z, Muchova J et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol®). Biomed Pharmacother 2006; 60: 5-9.
21. Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix-metalloproteinases by metabolites of maritime pine bark extract (Pycnogenol®). Free Radic Biol Med 2004; 36: 811-822.
22. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42: 23-30
23. Danesh J. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
24. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: A systematic review. Arch Intern Med 2007; 167: 31-39.
25. Koenig W. C-reactive protein - a critical cardiovascular risk marker. Nephrol Dial Transplant 2003; 18: 1039-1041.
26. Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221.
27. Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Joint Dis 2007; 65 (Suppl 1): S11-S15.
28. Fisher M, Cushman M, Knappertz V, Howard G. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J 2008; 156: 106-111.
29. Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: A predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-1659.
30. Devaraj S, Vega-Lopez S, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002; 37: 931-934.
31. Durackova Z, Trebaticky B, Novotny V, Zitnanova A, Breza J. Lipid metabolism and erectile function improvement by Pycnogenol® extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction - a pilot study. Nutr Res 2003; 23: 1189-1198.
32. Del Carlo Jr M, Loeser RF. Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species. Arthritis Rheum 2002; 46: 394-403.